Stay updated with breaking news from Hal Barron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GlaxoSmithKline's Vir-7831 treatment has been so successful that scientists have stopped the study early. The UK-based firm is seeking emergency use authorisation in the US.
Drug companies look to AI to end 'hit and miss' research Julia Kollewe © Provided by The Guardian Photograph: Sakchai Lalit/AP The hunt for new medicines has often been more like a game of roulette than high-end science. But now the pharmaceutical sector is on the cusp of a transformation, as it delves into cutting-edge technology to come up with new treatments for diseases such as cancer, rheumatoid arthritis and Alzheimer’s. Artificial intelligence (AI) is set to improve the industry’s success rates and speed up drug discovery, potentially saving it billions of dollar...
New agreement builds on existing collaboration to develop therapies for coronaviruses - News - PharmaTimes
GlaxoSmithKline has signed an agreement with Vir Biotechnology to expand their Covid-19 collaboration to advance new therapeutics for influenza.
Investegate announcements from GlaxoSmithKline PLC, GSK/Vir collaborate on antibodies for influenza